Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Lennard Hey

Nurse Practitioner, Primary Care Modesto, CA Nurse Practitioner

NPI 1295834778 CMS profile 684224

2501 McHenry Ave, Suite F, Modesto, CA 95350

Open in the dashboard

General payments

$230

13 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lennard Hey of Modesto, CA is reported in the CMS Open Payments database as having received $230 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $15 1
2021 General $191 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lennard Hey
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Lennard Hey were reported at $0. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Lennard Hey Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $191 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $15 $163 $53–$481 $160
2024 $24 $176 $54–$511 $164
2025 $0 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $89 4 payments
  2. Biohaven Pharmaceuticals, Inc. $30 2 payments
  3. Hologic, LLC $24 1 payment
  4. Janssen Pharmaceuticals, Inc $18 1 payment
  5. Novo Nordisk Inc $15 1 payment
  6. AstraZeneca Pharmaceuticals LP $15 1 payment
  7. Lilly USA, LLC $15 1 payment
  8. Sanofi-Aventis U.S. LLC $12 1 payment
  9. Sunovion Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $230 13 payments
Products named General payments · program years 2021–2024
  1. OFEV $51 2 payments
  2. JARDIANCE Diabetes $38 2 payments
  3. NURTEC ODT $30 2 payments
  4. THINPREP 2000 PROCESSOR $24 1 payment
  5. TRADJENTA $19 1 payment
  6. XARELTO $18 1 payment
  7. RYBELSUS $15 1 payment
  8. Ozempic $15 1 payment
  9. FARXIGA $15 1 payment
  10. JARDIANCE Diabetes $15 1 payment
  11. Other $38 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 117 drugs

Part D claims

5,581

Median for Nurse Practitioner: 389

Drug cost

$393,831

Median for Nurse Practitioner: $21,885

Branded share of claims

23.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 59 $57,730
Rybelsus Semaglutide Brand 59 $55,957
Eliquis Apixaban Brand 56 $46,133
Jardiance Empagliflozin Brand 60 $41,257
Farxiga Dapagliflozin Propanediol Brand 41 $29,403
Januvia Sitagliptin Phosphate Brand 32 $19,477
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $19,225
Janumet Sitagliptin Phos/Metformin Hcl Brand 20 $16,729
Xarelto Rivaroxaban Brand 16 $12,925
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $8,338

The 10 drugs with the highest cost, of 117 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record